- Home
- NRIX vs CSR Comparison
NRIX vs CSR Comparison
Compare NRIX & CSR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRIX
- CSR
- Stock Information
- Founded
- NRIX 2009
- CSR 1970
- Country
- NRIX United States
- CSR United States
- Employees
- NRIX N/A
- CSR N/A
- Industry
- NRIX Biotechnology: Pharmaceutical Preparations
- CSR Real Estate Investment Trusts
- Sector
- NRIX Health Care
- CSR Real Estate
- Exchange
- NRIX Nasdaq
- CSR Nasdaq
- Market Cap
- NRIX 908.0M
- CSR 1.0B
- IPO Year
- NRIX 2020
- CSR N/A
- Fundamental
- Price
- NRIX $11.71
- CSR $60.62
- Analyst Decision
- NRIX Strong Buy
- CSR Buy
- Analyst Count
- NRIX 16
- CSR 8
- Target Price
- NRIX $30.44
- CSR $72.13
- AVG Volume (30 Days)
- NRIX 771.2K
- CSR 111.3K
- Earning Date
- NRIX 07-10-2025
- CSR 07-28-2025
- Dividend Yield
- NRIX N/A
- CSR 5.08%
- EPS Growth
- NRIX N/A
- CSR N/A
- EPS
- NRIX N/A
- CSR N/A
- Revenue
- NRIX $56,417,000.00
- CSR $263,570,000.00
- Revenue This Year
- NRIX $16.69
- CSR $4.84
- Revenue Next Year
- NRIX N/A
- CSR $3.58
- P/E Ratio
- NRIX N/A
- CSR N/A
- Revenue Growth
- NRIX N/A
- CSR 2.19
- 52 Week Low
- NRIX $8.18
- CSR $54.13
- 52 Week High
- NRIX $29.56
- CSR $76.16
- Technical
- Relative Strength Index (RSI)
- NRIX 50.61
- CSR 38.35
- Support Level
- NRIX $11.17
- CSR $59.06
- Resistance Level
- NRIX $11.99
- CSR $61.68
- Average True Range (ATR)
- NRIX 0.60
- CSR 1.57
- MACD
- NRIX -0.10
- CSR -0.44
- Stochastic Oscillator
- NRIX 21.35
- CSR 17.25
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.
About CSR D/B/A Centerspace
Centerspace is a real estate investment trust (REIT) that focuses on the ownership, management, acquisitions, redevelopment, and development of apartment communities. The company operates through a single reportable segment which includes the ownership, management, development, redevelopment, and acquisition of apartment communities and conduct their corporate operations from offices in Minot, North Dakota and Minneapolis, Minnesota.